Description

Revumenib 160mg Tablet (LuciRevu) – Uses, Side Effects, Dosage & Price in Pakistan

Revumenib 160mg Tablet (LuciRevu) is a targeted cancer medicine containing revumenib, a menin inhibitor used to treat certain types of acute leukemia that have returned after treatment or have not responded to previous therapy. It works by blocking a protein interaction involved in the abnormal development of leukemia cells.

Revumenib may be prescribed to eligible patients with specific genetic changes, including a KMT2A translocation or a susceptible NPM1 mutation in acute myeloid leukemia (AML). Treatment eligibility depends on the patient’s diagnosis, genetic test results, previous treatments, and overall medical condition.

Patients searching for Revumenib 160mg Tablet in Pakistan should understand its approved uses, dosage requirements, possible side effects, and safety precautions before considering treatment. Impo Medic provides a point of contact for product-related enquiries, although current stock and local regulatory status must be confirmed directly.

Revumenib is a specialist prescription medicine and should only be used under the supervision of a qualified hematologist or oncologist.

What Is Revumenib 160mg Tablet (LuciRevu)?

Revumenib is an oral targeted therapy classified as a menin inhibitor. It interferes with the interaction between menin and KMT2A-related proteins, which can help maintain abnormal gene activity in certain leukemia cells.

The medicine is designed for specific forms of acute leukemia rather than all blood cancers. The 160mg strength identifies the amount of revumenib in the tablet, but it does not automatically determine the correct dose for an individual patient.

The exact manufacturer, packaging, and authenticity of LuciRevu should be verified with the supplier before purchase. The prescribing information for the approved US brand, Revuforj, provides the established medical guidance for revumenib; the identity and regulatory status of a differently branded product must be checked separately.

Uses of Revumenib 160mg Tablet

Revumenib is used for selected cases of relapsed or refractory acute leukemia. Relapsed leukemia means the disease has returned after treatment, while refractory leukemia means it has not responded adequately to treatment.

1. Acute Leukemia With a KMT2A Translocation

Revumenib is approved in the United States for adults and children aged one year and older with relapsed or refractory acute leukemia associated with a KMT2A gene translocation, identified using an appropriate diagnostic test.

This genetic alteration can disrupt normal blood-cell development and contribute to the growth of leukemia cells. Revumenib targets a pathway involved in this abnormal process.

2. Acute Myeloid Leukemia With an NPM1 Mutation

Revumenib is also approved in the United States for eligible adults and children aged one year and older with relapsed or refractory acute myeloid leukemia carrying a susceptible NPM1 mutation, when no satisfactory alternative treatment options are available.

Genetic testing and specialist assessment are essential to establish whether a patient meets the treatment criteria.

These are specific treatment indications. Revumenib should not be considered a general treatment for every type of leukemia. Regulatory approvals may vary by country, including Pakistan.

How Does Revumenib Work?

Revumenib blocks the interaction between menin and KMT2A-related proteins involved in abnormal gene regulation. In certain leukemia cells, this interaction helps maintain a disease-promoting pattern of gene expression and prevents normal cell maturation.

By inhibiting this interaction, revumenib can help restore aspects of normal cellular development and reduce the survival of susceptible leukemia cells.

The response differs between patients. Doctors monitor treatment using blood tests, bone marrow assessments, genetic findings, and the patient’s clinical condition. Revumenib does not guarantee remission or a cure.

Revumenib 160mg Tablet Dosage and Administration

The correct Revumenib dosage depends on the patient’s body weight, treatment indication, interacting medicines, and the prescribing specialist’s assessment. A 160mg tablet should not be interpreted as a complete dose for every patient.

For the approved revumenib product, administration is generally oral and twice daily. The precise regimen must follow the current prescribing information and the treating specialist’s instructions.

Important precautions include:

• Take the medicine exactly as prescribed.
• Follow the prescribed schedule and instructions about food.
• Do not change the dose or stop treatment independently.
• Ask the oncology team what to do if a dose is missed or vomiting occurs after taking the medicine.
• Do not alter the tablet’s physical form unless the product instructions and treating specialist permit it.
• Attend all scheduled laboratory tests and ECG appointments.

Certain medicines can affect revumenib levels and require dose modification. Patients should not calculate or adjust doses themselves, especially when strong CYP3A4 inhibitors are involved.

Side Effects of Revumenib 160mg Tablet

Revumenib can cause side effects that range from manageable symptoms to serious complications. The patient’s medical condition, other treatments, and blood counts may influence the risk.

Common or Reported Side Effects

Reported adverse reactions and laboratory abnormalities may include:

• Nausea
• Diarrhea or constipation
• Reduced appetite
• Fatigue or weakness
• Swelling or fluid retention
• Muscle or joint pain
• Infections
• Bleeding
• Changes in liver enzyme levels
• Changes in electrolyte levels
• Abnormal findings on blood tests

Not every patient will experience these effects. The oncology team can advise on symptom management and determine whether additional tests or treatment adjustments are needed.

Serious Side Effects

Differentiation syndrome: This potentially life-threatening reaction may cause fever, difficulty breathing, low oxygen levels, rapid weight gain, swelling, low blood pressure, or kidney problems. Seek urgent medical attention if these symptoms develop.

QT prolongation and abnormal heart rhythm: Revumenib can affect the heart’s electrical activity and may cause a dangerous rhythm disturbance. Fainting, severe dizziness, or a racing or irregular heartbeat requires urgent medical assessment.

Serious infection: Fever or other signs of infection can be particularly dangerous in patients with leukemia or low blood-cell counts. Contact the treating team promptly.

Bleeding: Unusual bruising, persistent bleeding, blood in the stool, or other unexpected bleeding should be reported immediately.

Patients should not attempt to treat suspected serious complications without medical help.

Warnings and Precautions Before Taking Revumenib

Heart Monitoring

Revumenib can prolong the QT interval and, in serious cases, cause a dangerous heart rhythm called torsades de pointes. The prescribing information requires ECG monitoring and correction of low potassium or magnesium levels. The medicine should not be initiated when the QTcF exceeds the specified threshold in the approved label.

Drug Interactions

Some medicines can increase revumenib exposure, while others may reduce its effectiveness. Strong CYP3A4 inhibitors may require dosage adjustment, and certain enzyme-inducing medicines should be avoided according to the prescribing information.

Tell the specialist about all prescription medicines, non-prescription products, vitamins, and herbal supplements.

Pregnancy and Breastfeeding

Revumenib may cause harm to an unborn baby. Patients who could become pregnant, and male patients whose partners could become pregnant, should discuss contraception with their healthcare professional. Breastfeeding should be avoided during treatment in accordance with the approved prescribing information.

Regular Medical Tests

Patients may need regular blood counts, liver function tests, electrolyte measurements, ECGs, and assessments for differentiation syndrome. Follow-up is an essential part of treatment and should not be skipped.

Who Should Take Revumenib?

Revumenib is intended for patients who meet specific treatment criteria for certain forms of acute leukemia. Genetic findings, previous treatment response, the patient’s age and weight, other medicines, and overall health all influence eligibility.

A diagnosis of leukemia alone does not mean that revumenib is appropriate. The treating specialist must review the diagnostic results and determine whether the expected benefits outweigh the risks.

Never use another person’s prescription or begin treatment based only on information found online.

Revumenib 160mg Tablet Price in Pakistan

The price of Revumenib 160mg Tablet (LuciRevu) in Pakistan may depend on the supplier, product origin, import arrangements, and current availability. A reliable current price should be requested directly from the supplier rather than inferred from another brand or an overseas listing.

Before purchasing this specialized oncology medicine, confirm the exact product name, strength, manufacturer, packaging, expiry date, authenticity documentation, and applicable regulatory requirements.

Revumenib 160mg Tablet Availability in Pakistan

Patients looking for Revumenib 160mg Tablet in Pakistan should confirm whether LuciRevu is currently available through an appropriate supply channel. Availability and registration status should not be assumed based on the availability of revumenib under a different brand in another country.

Impo Medic can be contacted to enquire about the product’s current availability and supporting product documentation. Confirm these details before placing an order, and consult the treating oncologist about sourcing and treatment requirements.

How to Buy Revumenib 160mg Tablet in Pakistan

You can contact Impo Medic to enquire about Revumenib 160mg Tablet (LuciRevu) and its availability in Pakistan. Stock and product documentation should be confirmed directly before ordering. Revumenib should only be used when prescribed by a qualified specialist for an appropriate leukemia diagnosis.

Why Choose Impo Medic?

Patients and caregivers sourcing specialized medicines need clear product information and a reliable way to enquire about availability. Impo Medic helps customers access medicine-related information and make product enquiries for the Pakistan market.

For Revumenib 160mg Tablet (LuciRevu), customers should confirm current stock, product identity, authenticity documentation, and applicable supply requirements directly. Impo Medic should not replace the medical advice of an oncology specialist, who remains responsible for determining eligibility, dosage, and ongoing monitoring.

Frequently Asked Questions About Revumenib 160mg Tablet (LuciRevu)

What is Revumenib 160mg Tablet used for?

Revumenib is a targeted medicine used for certain relapsed or refractory acute leukemias associated with a KMT2A translocation and for eligible cases of acute myeloid leukemia with a susceptible NPM1 mutation under the approved treatment criteria.

Is Revumenib a chemotherapy medicine?

Revumenib is classified as a targeted therapy called a menin inhibitor. It works by blocking a specific protein interaction involved in leukemia development rather than acting like conventional chemotherapy.

How should Revumenib 160mg Tablet be taken?

The approved revumenib medicine is generally taken by mouth twice daily. The appropriate dose depends on body weight, the treatment indication, and interacting medicines. Follow the specialist’s prescription and the applicable product instructions.

What are the serious side effects of Revumenib?

Serious risks include differentiation syndrome and QT prolongation, which can lead to dangerous heart rhythms. Fever, breathing difficulty, rapid swelling or weight gain, fainting, or an irregular heartbeat requires urgent medical assessment.

Is Revumenib suitable for all leukemia patients?

No. Revumenib is intended for specific acute leukemia subtypes and genetic findings. A hematologist or oncologist must confirm eligibility before treatment.

Is LuciRevu the same as Revuforj?

Revumenib is the active medicine associated with the approved US brand Revuforj. LuciRevu is the product name specified for this article, but its manufacturer, formulation, authenticity, and regulatory status should be independently verified rather than assumed to be identical.

Is Revumenib 160mg Tablet available in Pakistan?

Availability may change and cannot be confirmed from the medicine’s international approval alone. Contact Impo Medic to enquire about current LuciRevu availability and the documentation available for the specific product.

Can Revumenib be taken with other medicines?

Some medicines can change revumenib levels or increase the risk of heart-rhythm problems. Tell the treating specialist about all medicines and supplements before starting treatment or making any changes.

Does Revumenib cure leukemia?

Revumenib can produce a treatment response in some eligible patients, but a cure is not guaranteed. The outcome depends on the disease subtype, genetic characteristics, previous treatment, and individual response.